

Correction

Clinical Pharmacology
 in Drug Development
 2020, 9(7) 889–890
 © 2020, The American College of
 Clinical Pharmacology
 DOI: 10.1002/cpdd.861

Erpenbeck VJ, Vets E, Gheyle L, Osuntokun W, Larbig M, Neelakantham S, Sandham D, Dubois G, Elbast W, Goldsmith P, Weiss M. Pharmacokinetics, Safety, and Tolerability of Fevipiprant (QAW039), a Novel CRTh2 Receptor Antagonist: Results From 2 Randomized, Phase 1, Placebo-Controlled Studies in Healthy Volunteers. *Clin Pharmacol Drug Dev.* 2016 Jul;5(4):306–13

Explanation of the corrections:

The purity/drug content of the reference standard for the acyl glucuronide metabolite was previously over-estimated. Consequently, a correction factor of 0.76 was applied to revise these concentrations. These changes do not affect the conclusions or any other findings of the manuscript.

Content of the corrections (changed content in bold):

1. Methods
 - PK Assessments and Analysis (Pg 3, Line 32)
 - LLOQ for AG-metabolite was **1.52 ng/mL** in plasma and **3.8 ng/mL in urine**
2. Results
 - Pharmacokinetics (Pg 4, Line 19)
 - The AUC molar ratios (AG-metabolite/fevipiprant) **close to 1 suggests a comparable exposure to the metabolite** (Table 2)
3. Results
 - Food effect (Pg 4, Line 43)
 - The Ae_{0-120} molar ratio of metabolite to fevipiprant was **0.6–0.9** in fed and fasted states, similar to the 0.5–0.7 ratio in the multiple dose part (Table 3) and confirming the importance of urinary excretion as a route of elimination for both fevipiprant and its glucuronide metabolite and that CL_r is unaffected by food
4. Discussion (Pg 6, Line 23)
 - Renal clearance was an important route of elimination, with up to one-third of the dose excreted as fevipiprant in the urine; in addition, AG-metabolite **was found in urine**
5. Table 2. Summary of Pharmacokinetic (PK) parameters of Fevipiprant (PK Analysis Set) for the Single- and Multiple-Dose Studies (Pg 5)
 - AG-Metabolite/Fevipiprant (AUC_{τ} molar ratio^d) values for Fevipiprant Multiple-Dose Study. These should be:

Fevipiprant Multiple-Dose Study

Dose	AG-Metabolite/Fevipiprant AUC_{τ} molar ratio ^d
100 mg once daily	1.05 (0.15)
300 mg once daily	0.98 (0.13)
250 mg once daily	1.00 (0.06)

AUC_{τ} , AUC in the dosing interval; ^d AUC_{τ} AG-metabolite day 1 (μ M.h)/ AUC_{τ} fevipiprant day 1 (μ M.h)

6. Table 3. Urine Pharmacokinetic (PK) Parameters for Fevipiprant (PK Analysis Set)

- Molar Ratio^a values for Fevipiprant Multiple-Dose Study. These should be:

Fevipiprant Multiple-Dose Study	
Dose	Molar ratio ^a
100 mg once daily	0.6 (0.08)
300 mg once daily	0.5 (0.06)
250 mg twice daily	0.7 (0.09)

^aAe_{tau} AG-metabolite (day 7)/Ae_{tau} fevipiprant (day 7)

7. Figure 2. Mean plasma concentration–time profiles of (B) the acyl glucuronide metabolite (AG-metabolite) on log-linear scale in fed and fasted states.




Figure 2.